Pfizer Inc PFE

Revenue Intelligence Report • 58 quarters of SEC filing data • Updated 2026-03-06

Pfizer Inc's revenue is primarily influenced by its sales and marketing expenditures, with a notable elasticity indicating that a 1% increase in SG&A can lead to a 0.33% decrease in revenue. Despite the company's recent quarterly revenue of $17.6 billion, the holdout test revealed a significant prediction error, highlighting potential challenges in revenue forecasting. The FY forecast anticipates a revenue decline of 23.7% year-over-year, raising concerns about the effectiveness of current spending strategies. Investors should closely monitor the company's ability to optimize its expenditures and adapt to market conditions to improve overall return on investment.

Next FY Revenue

$47.76B

-23.7% YoY

SG&A Elasticity

-0.33x

Model Accuracy

25.4% MAPE

Holdout validation: The model predicted $11B vs the actual $18B — an error of 38.4%.

⚠ Model limitation: This company shows negative spending multipliers, meaning increases in spending have not directly translated into revenue growth. This typically occurs with commodity-driven companies or hypergrowth companies.

Note: Pfizer Inc does not report R&D expenses separately. This analysis uses SG&A spending only.

Investor insight: Actual revenue ($18B) came in 38% above the spending-based forecast ($11B). This suggests that Pfizer Inc's recent revenue growth is driven significantly by external demand factors — such as market pricing, product cycle tailwinds, or structural demand shifts — beyond what its R&D and SG&A spending alone would predict.

Revenue Forecast

Quarterly Detail

Quarter	Model Forecast	Actual	95% Range	YoY Growth	Status
Q4 2025	$11B	$18B	$6B – $21B	-39.1%	✓ In range
Q1 2026	$13B		$5B – $34B	-3.8%
Q2 2026	$11B		$4B – $36B	-22.5%
Q3 2026	$13B		$3B – $49B	-21.5%
Q4 2026	$10B		$2B – $44B	-42.3%

How Spending Drives Revenue

Reading this chart: Each line shows the cumulative elasticity — how a 1% increase in spending translates to revenue growth over subsequent quarters. The effect builds over 4-5 quarters as investments compound.

Want this analysis for your portfolio?

I build custom revenue intelligence reports for investors and companies using SEC filing data, econometric modeling, and AI-powered insights.

Get in Touch